Fanconi Anemia

Read full text Summarise with VIRAT
Authors: Filomena Pierri, Thierry M Leblanc, Carlo Dufour, Jean Soulier, Jean‐Hugues Dalle, Régis Peffault de Latour
Cited by: 0
References: 32

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Fanconi anemia (FA) is a rare inherited disorder marked by genomic instability, progressive bone marrow failure, congenital anomalies, and heightened cancer susceptibility. It results from mutations in genes involved in the FA/BRCA DNA repair pathway. FA diagnosis relies on chromosomal breakage assays and genetic testing, though somatic mosaicism and overlapping syndromes can complicate detection. Hematopoietic stem cell transplantation (HSCT) remains the only curative therapy for bone marrow failure and clonal evolution, with outcomes significantly improved through reduced-intensity conditioning and donor-matching strategies. Emerging options include haploidentical HSCT and gene therapy (GT). FA patients face increased risks of myeloid malignancies and solid tumors, particularly head and neck squamous cell carcinoma (HNSCC). Therefore, early surveillance, multidisciplinary care, and transplant timing are essential to optimize survival and reduce complications. Continued advances in genetic understanding, targeted therapies, and early diagnosis are critical to improving outcomes for individuals affected by FA.

Fields of Study & Subjects

DNA Repair Mechanisms Blood disorders and treatments Immunodeficiency and Autoimmune Disorders

Publication details

Journal / source
Springer eBooks
Pages
237–248
Publication date
25 March 2026
Language
EN
Document type
Book chapter